1. Home
  2. MED vs IPHA Comparison

MED vs IPHA Comparison

Compare MED & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MEDIFAST INC

MED

MEDIFAST INC

HOLD

Current Price

$12.18

Market Cap

140.0M

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.83

Market Cap

189.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MED
IPHA
Founded
1980
1999
Country
United States
France
Employees
N/A
163
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
140.0M
189.5M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
MED
IPHA
Price
$12.18
$1.83
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$12.00
$5.75
AVG Volume (30 Days)
154.9K
135.0K
Earning Date
05-04-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$934,842,000.00
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.22
$1.18
52 Week High
$15.37
$2.63

Technical Indicators

Market Signals
Indicator
MED
IPHA
Relative Strength Index (RSI) 49.71 51.54
Support Level $10.10 $1.69
Resistance Level $12.21 $1.84
Average True Range (ATR) 0.45 0.13
MACD -0.13 -0.02
Stochastic Oscillator 4.78 9.90

Price Performance

Historical Comparison
MED
IPHA

About MED MEDIFAST INC

Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: